Scribd Logo
Upload

Welcome to Scribd!

  • Cancer Type Mature Vs Immature Antigen Rout of Administration Clinical Response Conclusion

    Uploaded by

    Samarth Shetty
    2 views1 page
    This document discusses different methods for maturing dendritic cells (DCs) to use in cancer immunotherapies. It provides a table comparing 8 maturation protocols for DCs and their ability to induce maturation. The document also summarizes two studies on using DCs to generate anti-tumor immune responses in melanoma patients, finding some success inducing immunity but noting DCs can also exhibit immunosuppressive properties and relation to tumor angiogenesis.

    Original Description:

    Plan

    Original Title

    Plan

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This document discusses different methods for maturing dendritic cells (DCs) to use in cancer immunotherapies. It provides a table comparing 8 maturation protocols for DCs and their ability to induce maturation. The document also summarizes two studies on using DCs to generate anti-tumor immune responses in melanoma patients, finding some success inducing immunity but noting DCs can also exhibit immunosuppressive properties and relation to tumor angiogenesis.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    2 views1 page

    Cancer Type Mature Vs Immature Antigen Rout of Administration Clinical Response Conclusion

    Uploaded by

    Samarth Shetty
    This document discusses different methods for maturing dendritic cells (DCs) to use in cancer immunotherapies. It provides a table comparing 8 maturation protocols for DCs and their ability to induce maturation. The document also summarizes two studies on using DCs to generate anti-tumor immune responses in melanoma patients, finding some success inducing immunity but noting DCs can also exhibit immunosuppressive properties and relation to tumor angiogenesis.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    Cancer type Mature vs Antigen Rout of Clinical Conclusion

    Immature Administration Response


    Melanoma (1) Immature Autologous Intranodally 5/16 (31%)
    tumour lysates

    Table 1: Maturation Protocols

    Maturation Protocol Maturation status


    TNF-, PGE2 Minimal
    TNF-, CD40L Standard
    IFN-, TNF- Standard
    IL-1, IL-6, TNF-, PGE2 Standard
    IFN-, CD40L Optimal
    IFN-, TNF-, CD40L Optimal
    IL1, 6, TNF-, IFN-, CD40L Optimal
    IL1, 6, TNF-, IFN-, PGE2, CD40L Optimal

    1. Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, et al. Phase 1 study in
    patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived
    from the melanoma-associated antigens MART-1 and gp100. J Immunother. 2000;23(4):487-98.

    Cancer Type Method Results Conclusion


    Melanoma Immature DC 16/16 immunity

    In several studies tumour associated DCs were immunosuppressive.

    DCs also related to tumour angiogenesis

    You might also like